Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.7K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

13.8K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

13.9K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.2K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

5.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.

Pharmacological research·2020
Same author

Exosomes derived from miRNA-210 overexpressing bone marrow mesenchymal stem cells protect lipopolysaccharide induced chondrocytes injury via the NF-κB pathway.

Gene·2020
Same author

Aberrant Hippocampal Functional Connectivity Is Associated with Fornix White Matter Integrity in Alzheimer's Disease and Mild Cognitive Impairment.

Journal of Alzheimer's disease : JAD·2020
Same author

Limonoids and tricyclic diterpenoids from Azadirachta indica and their antitumor activities.

Bioorganic chemistry·2020
Same author

Self-supporting hierarchical PdCu aerogels for enhanced catalytic reduction of 4-nitrophenol.

Journal of hazardous materials·2020
Same author

[Analysis of cortical density in zygomatic alveolar ridge of different vertical facial types].

Shanghai kou qiang yi xue = Shanghai journal of stomatology·2020

Related Experiment Video

Updated: Sep 30, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.0K

OGT as potential novel target: Structure, function and inhibitors.

Ning Zhang1, Hongli Jiang1, Kexin Zhang1

  • 1Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China.

Chemico-Biological Interactions
|March 15, 2022
PubMed
Summary
This summary is machine-generated.

O-linked N-acetylglucosamine transferase (OGT) regulates biological processes. OGT inhibitors are crucial for understanding O-GlcNAcylation mechanisms and developing treatments for related diseases.

Keywords:
O-GlcNAcylationO-Linked N-acetylglucosamine transferaseOGT inhibitors

More Related Videos

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

413
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

6.8K

Related Experiment Videos

Last Updated: Sep 30, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.0K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

413
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

6.8K

Area of Science:

  • Glycobiology
  • Molecular Biology
  • Biochemistry

Background:

  • O-linked N-acetylglucosamine transferase (OGT) is central to O-GlcNAcylation, a post-translational modification regulating diverse biological functions.
  • OGT's role in cellular signaling and disease pathogenesis makes it a significant target in glycobiology research.

Purpose of the Study:

  • To provide a comprehensive overview of O-linked N-acetylglucosamine transferase (OGT), covering its basic information, disease associations, and inhibitor development.
  • To elucidate the structural aspects of OGT to enhance understanding of its function and therapeutic potential.
  • To highlight the utility of OGT inhibitors in dissecting the O-GlcNAcylation pathway and informing disease treatment strategies.

Main Methods:

  • Literature review focusing on OGT structure, function, and disease relevance.
  • Analysis of current research on OGT inhibitors and their mechanisms of action.
  • Synthesis of information to connect OGT structure with its biological roles and therapeutic targeting.

Main Results:

  • Detailed information on OGT structure and its role in catalyzing O-GlcNAcylation.
  • Established links between OGT dysregulation and various pathological conditions.
  • Overview of the progress and potential of OGT inhibitors in research and therapeutic development.

Conclusions:

  • Understanding OGT's structure is key to comprehending O-GlcNAcylation.
  • OGT inhibitors offer valuable tools for mechanistic studies and potential therapeutic interventions.
  • Further research into OGT and its inhibitors can advance glycobiology and disease treatment.